Compare DSP & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSP | IKT |
|---|---|---|
| Founded | 1999 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 272.1M | 209.3M |
| IPO Year | 2021 | 2020 |
| Metric | DSP | IKT |
|---|---|---|
| Price | $10.15 | $1.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 9 |
| Target Price | ★ $19.32 | $5.55 |
| AVG Volume (30 Days) | 418.3K | ★ 515.3K |
| Earning Date | 11-09-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 157.14 | 57.76 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $344,201,000.00 | N/A |
| Revenue This Year | $26.56 | N/A |
| Revenue Next Year | $20.92 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.00 | N/A |
| 52 Week Low | $8.72 | $1.29 |
| 52 Week High | $14.80 | $2.61 |
| Indicator | DSP | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 32.55 | 33.23 |
| Support Level | $9.75 | N/A |
| Resistance Level | $12.45 | $1.71 |
| Average True Range (ATR) | 0.84 | 0.12 |
| MACD | -0.26 | -0.01 |
| Stochastic Oscillator | 1.15 | 2.25 |
Viant Technology Inc is an advertising technology company engaged in providing a cloud-based demand-side platform (DSP) for programmatic advertising. The company enables marketers and advertising agencies to plan, buy, and measure digital advertising campaigns across multiple channels, including connected TV, streaming audio, mobile, desktop, and digital out-of-home. Its platform leverages data integrations and proprietary identity solutions to deliver targeted advertising, audience insights, and performance measurement.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.